Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study

Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is lim...

Full description

Bibliographic Details
Authors: Almeida, Antonio M., Prebet, Thomas, Itzykson, Raphael, Ramos, Fernando, Al-Ali, Haifa, Shammo, Jamile, Pinto, Ricardo, Maurillo, Luca, Wetzel, Jaime, Musto, Pellegrino, Van De Loosdrecht, Arjan A., Costa, Maria Joao, Esteves, Susana, Burgstaller, Sonja, Stauder, Reinhard, Autzinger, Eva M., Lang, Alois, Krippl, Peter, Geissler, Dietmar, Falantes, Jose F., Pedro, Carmen, Bargay Lleonart, Joan, Deben, Guillermo, Garrido, Ana, Bonanad, Santiago, Diez-Campelo, Maria, Thepot, Sylvain, Ades, Lionel, Sperr, Wolfgang R., Valent, Peter, Fenaux, Pierre, Sekeres, Mikkael A., Greil, Richard, Pleyer, Lisa
Format: article
Publication Date:2017
Country:España
Institution:Conselleria de Salut i Consum del Govern de les Illes Balears
Repository:Docusalut
Language:English
OAI Identifier:oai:docusalut.com:20.500.13003/9895
Online Access:https://hdl.handle.net/20.500.13003/9895
Access Level:Open access
Keyword:Decitabine
Female
Proportional Hazards Models
Retrospective Studies
Leukemia, Erythroblastic, Acute
Aged, 80 and over
Aged
Bone Marrow
Azacitidine
Male
Humans
Cytogenetic Analysis
Antineoplastic Combined Chemotherapy Protocols
Middle Aged
Biomarkers
Survival Analysis
Adult
Treatment Outcome
Leucemia Eritroblástica Aguda
Modelos de Riesgos Proporcionales
Resultado del Tratamiento
Biomarcadores
Análisis Citogenético
Análisis de Supervivencia
Femenino
Decitabina
Masculino
Azacitidina
Humanos
Persona de Mediana Edad
Protocolos de Quimioterapia Combinada Antineoplásica
Anciano
Anciano de 80 o más Años
Médula Ósea
Estudios Retrospectivos
Adulto
acute erythroleukemia
azacitidine
decitabine
id ES_0da9f162d41b25979ea1fde4672fb102
oai_identifier_str oai:docusalut.com:20.500.13003/9895
network_acronym_str ES
network_name_str España
repository_id_str
spelling Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational StudyAlmeida, Antonio M.Prebet, ThomasItzykson, RaphaelRamos, FernandoAl-Ali, HaifaShammo, JamilePinto, RicardoMaurillo, LucaWetzel, JaimeMusto, PellegrinoVan De Loosdrecht, Arjan A.Costa, Maria JoaoEsteves, SusanaBurgstaller, SonjaStauder, ReinhardAutzinger, Eva M.Lang, AloisKrippl, PeterGeissler, DietmarFalantes, Jose F.Pedro, CarmenBargay Lleonart, JoanDeben, GuillermoGarrido, AnaBonanad, SantiagoDiez-Campelo, MariaThepot, SylvainAdes, LionelSperr, Wolfgang R.Valent, PeterFenaux, PierreSekeres, Mikkael A.Greil, RichardPleyer, LisaDecitabineFemaleProportional Hazards ModelsRetrospective StudiesLeukemia, Erythroblastic, AcuteAged, 80 and overAgedBone MarrowAzacitidineMaleHumansCytogenetic AnalysisAntineoplastic Combined Chemotherapy ProtocolsMiddle AgedBiomarkersSurvival AnalysisAdultTreatment OutcomeAged, 80 and overLeucemia Eritroblástica AgudaModelos de Riesgos ProporcionalesResultado del TratamientoBiomarcadoresAnálisis CitogenéticoAnálisis de SupervivenciaFemeninoDecitabinaMasculinoAzacitidinaHumanosPersona de Mediana EdadProtocolos de Quimioterapia Combinada AntineoplásicaAncianoAnciano de 80 o más AñosMédula ÓseaEstudios RetrospectivosAdultoacute erythroleukemiaazacitidinedecitabineAcute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p <= 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7 months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL.MDPI20172017-04-0120172017-04-01research articlehttp://purl.org/coar/resource_type/c_2df8fbb1info:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/20.500.13003/9895reponame:Docusalutinstname:Conselleria de Salut i Consum del Govern de les Illes BalearsInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:docusalut.com:20.500.13003/98952026-06-22T12:44:07Z
dc.title.none.fl_str_mv Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
title Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
spellingShingle Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
Almeida, Antonio M.
Decitabine
Female
Proportional Hazards Models
Retrospective Studies
Leukemia, Erythroblastic, Acute
Aged, 80 and over
Aged
Bone Marrow
Azacitidine
Male
Humans
Cytogenetic Analysis
Antineoplastic Combined Chemotherapy Protocols
Middle Aged
Biomarkers
Survival Analysis
Adult
Treatment Outcome
Aged, 80 and over
Leucemia Eritroblástica Aguda
Modelos de Riesgos Proporcionales
Resultado del Tratamiento
Biomarcadores
Análisis Citogenético
Análisis de Supervivencia
Femenino
Decitabina
Masculino
Azacitidina
Humanos
Persona de Mediana Edad
Protocolos de Quimioterapia Combinada Antineoplásica
Anciano
Anciano de 80 o más Años
Médula Ósea
Estudios Retrospectivos
Adulto
acute erythroleukemia
azacitidine
decitabine
title_short Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
title_full Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
title_fullStr Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
title_full_unstemmed Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
title_sort Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study
dc.creator.none.fl_str_mv Almeida, Antonio M.
Prebet, Thomas
Itzykson, Raphael
Ramos, Fernando
Al-Ali, Haifa
Shammo, Jamile
Pinto, Ricardo
Maurillo, Luca
Wetzel, Jaime
Musto, Pellegrino
Van De Loosdrecht, Arjan A.
Costa, Maria Joao
Esteves, Susana
Burgstaller, Sonja
Stauder, Reinhard
Autzinger, Eva M.
Lang, Alois
Krippl, Peter
Geissler, Dietmar
Falantes, Jose F.
Pedro, Carmen
Bargay Lleonart, Joan
Deben, Guillermo
Garrido, Ana
Bonanad, Santiago
Diez-Campelo, Maria
Thepot, Sylvain
Ades, Lionel
Sperr, Wolfgang R.
Valent, Peter
Fenaux, Pierre
Sekeres, Mikkael A.
Greil, Richard
Pleyer, Lisa
author Almeida, Antonio M.
author_facet Almeida, Antonio M.
Prebet, Thomas
Itzykson, Raphael
Ramos, Fernando
Al-Ali, Haifa
Shammo, Jamile
Pinto, Ricardo
Maurillo, Luca
Wetzel, Jaime
Musto, Pellegrino
Van De Loosdrecht, Arjan A.
Costa, Maria Joao
Esteves, Susana
Burgstaller, Sonja
Stauder, Reinhard
Autzinger, Eva M.
Lang, Alois
Krippl, Peter
Geissler, Dietmar
Falantes, Jose F.
Pedro, Carmen
Bargay Lleonart, Joan
Deben, Guillermo
Garrido, Ana
Bonanad, Santiago
Diez-Campelo, Maria
Thepot, Sylvain
Ades, Lionel
Sperr, Wolfgang R.
Valent, Peter
Fenaux, Pierre
Sekeres, Mikkael A.
Greil, Richard
Pleyer, Lisa
author_role author
author2 Prebet, Thomas
Itzykson, Raphael
Ramos, Fernando
Al-Ali, Haifa
Shammo, Jamile
Pinto, Ricardo
Maurillo, Luca
Wetzel, Jaime
Musto, Pellegrino
Van De Loosdrecht, Arjan A.
Costa, Maria Joao
Esteves, Susana
Burgstaller, Sonja
Stauder, Reinhard
Autzinger, Eva M.
Lang, Alois
Krippl, Peter
Geissler, Dietmar
Falantes, Jose F.
Pedro, Carmen
Bargay Lleonart, Joan
Deben, Guillermo
Garrido, Ana
Bonanad, Santiago
Diez-Campelo, Maria
Thepot, Sylvain
Ades, Lionel
Sperr, Wolfgang R.
Valent, Peter
Fenaux, Pierre
Sekeres, Mikkael A.
Greil, Richard
Pleyer, Lisa
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv Decitabine
Female
Proportional Hazards Models
Retrospective Studies
Leukemia, Erythroblastic, Acute
Aged, 80 and over
Aged
Bone Marrow
Azacitidine
Male
Humans
Cytogenetic Analysis
Antineoplastic Combined Chemotherapy Protocols
Middle Aged
Biomarkers
Survival Analysis
Adult
Treatment Outcome
Aged, 80 and over
Leucemia Eritroblástica Aguda
Modelos de Riesgos Proporcionales
Resultado del Tratamiento
Biomarcadores
Análisis Citogenético
Análisis de Supervivencia
Femenino
Decitabina
Masculino
Azacitidina
Humanos
Persona de Mediana Edad
Protocolos de Quimioterapia Combinada Antineoplásica
Anciano
Anciano de 80 o más Años
Médula Ósea
Estudios Retrospectivos
Adulto
acute erythroleukemia
azacitidine
decitabine
topic Decitabine
Female
Proportional Hazards Models
Retrospective Studies
Leukemia, Erythroblastic, Acute
Aged, 80 and over
Aged
Bone Marrow
Azacitidine
Male
Humans
Cytogenetic Analysis
Antineoplastic Combined Chemotherapy Protocols
Middle Aged
Biomarkers
Survival Analysis
Adult
Treatment Outcome
Aged, 80 and over
Leucemia Eritroblástica Aguda
Modelos de Riesgos Proporcionales
Resultado del Tratamiento
Biomarcadores
Análisis Citogenético
Análisis de Supervivencia
Femenino
Decitabina
Masculino
Azacitidina
Humanos
Persona de Mediana Edad
Protocolos de Quimioterapia Combinada Antineoplásica
Anciano
Anciano de 80 o más Años
Médula Ósea
Estudios Retrospectivos
Adulto
acute erythroleukemia
azacitidine
decitabine
description Acute erythroleukemia (AEL) is a rare disease typically associated with a poor prognosis. The median survival ranges between 3-9 months from initial diagnosis. Hypomethylating agents (HMAs) have been shown to prolong survival in patients with myelodysplastic syndromes (MDS) and AML, but there is limited data of their efficacy in AEL. We collected data from 210 AEL patients treated at 28 international sites. Overall survival (OS) and PFS were estimated using the Kaplan-Meier method and the log-rank test was used for subgroup comparisons. Survival between treatment groups was compared using the Cox proportional hazards regression model. Eighty-eight patients were treated with HMAs, 44 front line, and 122 with intensive chemotherapy (ICT). ICT led to a higher overall response rate (complete or partial) compared to first-line HMA (72% vs. 46.2%, respectively; p <= 0.001), but similar progression-free survival (8.0 vs. 9.4 months; p = 0.342). Overall survival was similar for ICT vs. HMAs (10.5 vs. 13.7 months; p = 0.564), but patients with high-risk cytogenetics treated with HMA first-line lived longer (7.5 for ICT vs. 13.3 months; p = 0.039). Our results support the therapeutic value of HMA in AEL.
publishDate 2017
dc.date.none.fl_str_mv 2017
2017-04-01
2017
2017-04-01
dc.type.none.fl_str_mv research article
http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://hdl.handle.net/20.500.13003/9895
url https://hdl.handle.net/20.500.13003/9895
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Docusalut
instname:Conselleria de Salut i Consum del Govern de les Illes Balears
instname_str Conselleria de Salut i Consum del Govern de les Illes Balears
reponame_str Docusalut
collection Docusalut
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403352445485056
score 15.812455

Similar Items